business
Abbott Laboratories (ABT) must face a Lawsuit over PediaSure, Statements about Children’s Growth
Key takeaways
- US District Judge Paul Engelmayer said labeling featuring a giraffe and ruler-like marks could lead consumers to interpret "grow" as height gain, while "gain" implied weight.
- In a 75-page decision, Engelmayer noted jurors could find the firm's commercials reinforced that message, citing an ad showing a boy comparing himself to taller peers.
- The corporation said its labeling is "appropriate" and backed by evidence, maintaining PediaSure supports children's growth and development.
Abbott Laboratories (ABT) must face a Lawsuit over Pedia Sure, Statements about Children’s Growth Fatima Gulzar Sat, June 27, 2026 at 10:32 PM GMT+7 1 min read ABT Abbott Laboratories (NYSE:ABT) is among the Best Brain-Computer Interface Stocks.
On June 4, Reuters reported a federal judge ruled that Abbott Laboratories (NYSE:ABT) must face a proposed class-action lawsuit alleging it misled consumers by marketing Pedia Sure Grow & Gain drinks as "clinically proven" to help children grow.
US District Judge Paul Engelmayer said labeling featuring a giraffe and ruler-like marks could lead consumers to interpret "grow" as height gain, while "gain" implied weight. Hence, the claims will proceed, and Abbott Laboratories (NYSE:ABT) must defend.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop